UNIGE document Scientific Article
previous document  unige:112377  next document
add to browser collection

Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study

Battegay, Manuel
Cavassini, Matthias
Fehr, Jan
Hirzel, Cedric
show hidden authors show all authors [1 - 9]
Published in BMC Infectious Diseases. 2017, vol. 17, no. 1, p. 476
Abstract Rilpivirine is safe and effective in HIV-naïve patients with low baseline HIV-RNA or in switch strategy. It offers the advantages of few drug-drug interactions and a favourable toxicity profile. We aimed to determine the reasons for prescribing the rilpivirine (RPV)/tenofovir disoproxil (TDF)/emtricitabine (FTC) co-formulation within the Swiss HIV Cohort Study and to assess its effectiveness and safety over a 24 months period.
Keywords AdultAnti-HIV Agents/therapeutic useAntiretroviral TherapyHighly Active/methodsBenzoxazines/adverse effectsCD4 Lymphocyte CountDrug CombinationsEmtricitabine/therapeutic useFemaleHIV Infections/drug therapyHIV-1/geneticsHumansMaleMiddle AgedProspective StudiesRilpivirine/therapeutic useTenofovir/therapeutic useTreatment OutcomeViral Load
PMID: 28683720
Full text
Article (Published version) (614 Kb) - public document Free access
Research groups Epidémiologie clinique (115)
VIH/SIDA (930)
(ISO format)
SCULIER, Delphine et al. Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study. In: BMC Infectious Diseases, 2017, vol. 17, n° 1, p. 476. doi: 10.1186/s12879-017-2579-2 https://archive-ouverte.unige.ch/unige:112377

249 hits



Deposited on : 2018-12-18

Export document
Format :
Citation style :